The organ shortage for kidney transplantation remains a challenging issue worldwide. Incompatibility
between donor-recipient pairs, commonly occurring among transplant candidates who were sensitized from prior
antigen exposure, serves as a significant barrier to kidney transplantation. In efforts to overcome this obstacle,
living and deceased donor kidney transplantation across human leukocyte antigen barriers following desensitization
has been pursued via positive crossmatch transplantation. The goal of desensitization therapy is to remove or
denigrate donor-specific alloantibodies prior to transplantation in order to permit transplantation across the human
leukocyte antigen barrier and prevent rejection. Various desensitization regimens have been utilized, including
the use of plasmapheresis, intravenous immunoglobulin, and or immunoadsorption. Although long-term allograft
outcomes for positive crossmatch kidney transplantation following desensitization therapy have been shown to be
inferior to compatible transplantation, particularly with increasing strength of the crossmatch, there is an established
survival benefit for positive crossmatch transplant recipients compared with remaining on the transplant
waitlist. However, positive crossmatch transplantation may confer higher risks of infection and malignancy. Despite
the fact that some of these heightened risks, positive crossmatch transplantation has also been demonstrated
to have cost-savings compared with remaining on dialysis and may, therefore, be a cost-effective treatment option
for sensitized patients who would face long waiting times and may never be able to achieve compatible transplantation.
This review highlights both the risks and benefits of positive crossmatch transplantation and its role in the
broader field of kidney transplantation.
Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation